“…Recently, the use of chimeric antigen receptor engineered T-cell therapy (CAR-T) has shown great promise in the treatment of MM, including approaches targeting B-cell maturation antigen (BCMA) [ 52 ], CD138 [ 53 ], CD19 [ 54 ], orphan G protein-coupled receptor, class C group 5 member D (GPRC5D) [ 55 ], which showed significantly improved activity, including a sustained and profound response. For targets currently being investigated in preclinical or clinical trials for MM, see the comprehensive review by previous researchers [ [56] , [57] , [58] ] where the authors provided a comprehensive overview of CAR-T targets for MM, which include CD138, CD38, CS1, CD19, kappa light chain, CD56, CD44v6, Lewis Y, NY-ESO-1, CD229 ( Table 1 ). Therefore, we omit this information here to avoid repeating its already published content.…”